We wanted to investigate if it might be advantageous to block PD-1 expression that occurs at the time of initial T-cell activation with vaccination, and potentially not permit the activated cells to become dysfunctional within a PD-L1-expressing tumor microenvironment [18, 23]. Here, CD274 is linked to neoplasm.